Assessment of an Anticancer Effect of the Simultaneous Administration of MM-129 and Indoximod in the Colorectal Cancer Model
- PMID: 38201550
- PMCID: PMC10778160
- DOI: 10.3390/cancers16010122
Assessment of an Anticancer Effect of the Simultaneous Administration of MM-129 and Indoximod in the Colorectal Cancer Model
Abstract
(1) Background: The purpose of the given study was to examine the antitumor activity of the simultaneous administration of MM-129, a 1,2,4-triazine derivative, and indoximod (IND), the kynurenine pathway inhibitor, toward colon cancer. (2) Methods: The efficiency of the co-administration of the studied compounds was assessed in xenografted zebrafish embryos. Then, the effects of the combined administration of compounds on cellular processes such as cell viability, apoptosis, and intracellular signaling pathways were evaluated. In vitro studies were performed using two colorectal cancer cell lines, namely, DLD-1 and HT-29. (3) Results: The results indicated that the simultaneous application of MM-129 and indoximod induced a stronger inhibition of tumor growth in zebrafish xenografts. The combination of these compounds intensified the process of apoptosis by lowering the mitochondrial potential, enhancing the externalization of phosphatidylserine (PS) and activation of caspases. Additionally, the expression of protein kinase B (AKT) and indoleamine 2,3-dioxygenase-(1IDO1) was disrupted under the applied compound combination. (4) Conclusions: Simultaneous targeting of ongoing cell signaling that promotes tumor progression, along with inhibition of the kynurenine pathway enzyme IDO1, results in the enhancement of the antitumor effect of the tested compounds against the colon cancer cells.
Keywords: MM-129; colon cancer; immunooncology; indoximod; kynurenine pathway; zebrafish.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures






Similar articles
-
IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.Cancer Res. 2019 Mar 15;79(6):1138-1150. doi: 10.1158/0008-5472.CAN-18-0668. Epub 2019 Jan 24. Cancer Res. 2019. PMID: 30679179 Free PMC article.
-
Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms.BMC Cancer. 2023 Jan 18;23(1):62. doi: 10.1186/s12885-023-10539-5. BMC Cancer. 2023. PMID: 36653774 Free PMC article.
-
IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.Gastroenterology. 2013 Aug;145(2):416-25.e1-4. doi: 10.1053/j.gastro.2013.05.002. Epub 2013 May 10. Gastroenterology. 2013. PMID: 23669411 Free PMC article.
-
Trial watch: IDO inhibitors in cancer therapy.Oncoimmunology. 2020 Jun 14;9(1):1777625. doi: 10.1080/2162402X.2020.1777625. Oncoimmunology. 2020. PMID: 32934882 Free PMC article. Review.
-
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer.Front Oncol. 2018 Sep 11;8:370. doi: 10.3389/fonc.2018.00370. eCollection 2018. Front Oncol. 2018. PMID: 30254983 Free PMC article. Review.
Cited by
-
Synthesis, anticancer evaluation, and electrochemical investigation of new chiral pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides.Sci Rep. 2025 May 28;15(1):18640. doi: 10.1038/s41598-025-02835-w. Sci Rep. 2025. PMID: 40436919 Free PMC article.
References
-
- Kiyozumi Y., Baba Y., Okadome K., Yagi T., Ishimoto T., Iwatsuki M., Miyamoto Y., Yoshida N., Watanabe M., Komohara Y., et al. IDO1 Expression Is Associated with Immune Tolerance and Poor Prognosis in Patients with Surgically Resected Esophageal Cancer. Ann. Surg. 2019;269:1101–1108. doi: 10.1097/SLA.0000000000002754. - DOI - PubMed
-
- D’Amato N.C., Rogers T.J., Gordon M.A., Greene L.I., Cochrane D.R., Spoelstra N.S., Nemkov T.G., D’Alessandro A., Hansen K.C., Richer J.K. A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2015;75:4651–4664. doi: 10.1158/0008-5472.CAN-15-2011. - DOI - PMC - PubMed
-
- Thaker A.I., Rao M.S., Bishnupuri K.S., Kerr T.A., Foster L., Marinshaw J.M., Newberry R.D., Stenson W.F., Ciorba M.A. IDO1 Metabolites Activate β-Catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice. Gastroenterology. 2013;145:416–425.e4. doi: 10.1053/j.gastro.2013.05.002. - DOI - PMC - PubMed
-
- Bishnupuri K.S., Alvarado D.M., Khouri A.N., Shabsovich M., Chen B., Dieckgraefe B.K., Ciorba M.A. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. Cancer Res. 2019;79:1138–1150. doi: 10.1158/0008-5472.CAN-18-0668. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous